Galderma launches tests on liquid botulinum toxin product therapy

Galderma has initiated a phase II clinical trial on a liquid formulation of botulinum toxin to be used in aesthetic dermatology and cosmetic surgery.

The multi-centre dose-ranging study is designed to evaluate the safety and effectiveness of Galderma’s internally developed liquid form of botulinum toxin for the treatment of glabellar lines.

Galderma officials say a liquid formulation has the potential to offer physicians a ready-to-use product that may result in a better patient experience and improved outcomes.

Galderma president and chief executive officer Humberto Antunes said, “The development of a liquid neurotoxin represents a significant advancement over existing commercial products and would allow us to further strengthen our position in the aesthetic category by better meeting physician and patient needs.”